Historical retrospective of the SRC oncogene and new perspectives (Review)

Simatou,Aristofania; Simatos,George; Goulielmaki,Maria; Spandidos,Demetrios   A.; Baliou,Stella; Zoumpourlis,Vassilios

doi:10.3892/mco.2020.2091

Historical retrospective of the SRC oncogene and new perspectives (Review)

Authors:
- Aristofania Simatou
- George Simatos
- Maria Goulielmaki
- Demetrios A. Spandidos
- Stella Baliou
- Vassilios Zoumpourlis
View Affiliations

Affiliations: First Breast Unit, Saint Savas Cancer Hospital, 11522 Athens, Greece, Biomedical Applications Unit, Institute of Chemical Biology, National Hellenic Research Foundation (NHRF), 11635 Athens, Greece, Laboratory of Clinical Virology, Medical School, University of Crete, 71003 Heraklion, Greece
Published online on: July 14, 2020 https://doi.org/10.3892/mco.2020.2091
Article Number: 21
Copyright: © Simatou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Since its first discovery as part of the Rous sarcoma virus (RSV) genome, the c‑SRC (SRC) proto‑oncogene has been proved a key regulator of cancer development and progression, and thus it has been highlighted as an attractive target for anti‑cancer therapeutic strategies. Though the exact mechanisms of its action are still not fully understood, SRC protein mediates crucial normal cell functions, such as cell development, proliferation and survival, and its dysregulation is considered as an oncogenic signature and a driving force for cancer initiation. In the present review, we present a flashback to the history of the Src research, while focusing on the most important milestones in the field. Moreover, we investigate the proposed regulatory mechanisms and molecules that mediate its action in order to designate putative therapeutic targets and useful prognostic and/or diagnostic tools. Furthermore, we present and discuss existing therapeutic approaches that are explored in clinical settings.

View Figures

View References

1	Frame MC: Src in cancer: Deregulation and consequences for cell behaviour. Biochim Biophys Acta. 1602:114–130. 2002.PubMed/NCBI View Article : Google Scholar
2	Ishizawar R and Parsons SJ: c-Src and cooperating partners in human cancer. Cancer Cell. 6:209–214. 2004.PubMed/NCBI View Article : Google Scholar
3	Summy JM and Gallick GE: Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 22:337–358. 2003.PubMed/NCBI View Article : Google Scholar
4	Irby RB and Yeatman TJ: Role of Src expression and activation in human cancer. Oncogene. 19:5636–5642. 2000.PubMed/NCBI View Article : Google Scholar
5	Yeatman TJ: A renaissance for SRC. Nat Rev Cancer. 4:470–480. 2004.PubMed/NCBI View Article : Google Scholar
6	Kim LC, Song L and Haura EB: Src kinases as therapeutic targets for cancer. Nat Rev Clin Oncol. 6:587–595. 2009.PubMed/NCBI View Article : Google Scholar
7	Krishnan H, Miller WT and Goldberg GS: SRC points the way to biomarkers and chemotherapeutic targets. Genes Cancer. 3:426–435. 2012.PubMed/NCBI View Article : Google Scholar
8	Brown MT and Cooper JA: Regulation, substrates and functions of src. Biochim Biophys Acta. 1287:121–149. 1996.PubMed/NCBI View Article : Google Scholar
9	Playford MP and Schaller MD: The interplay between Src and integrins in normal and tumor biology. Oncogene. 23:7928–7946. 2004.PubMed/NCBI View Article : Google Scholar
10	Hakak Y and Martin GS: Ubiquitin-dependent degradation of active Src. Curr Biol. 9:1039–1042. 1999.PubMed/NCBI View Article : Google Scholar
11	Laszlo GS and Cooper JA: Restriction of Src activity by Cullin-5. Curr Biol. 19:157–162. 2009.PubMed/NCBI View Article : Google Scholar
12	Okada M, Nada S, Yamanashi Y, Yamamoto T and Nakagawa H: CSK: A protein-tyrosine kinase involved in regulation of src family kinases. J Biol Chem. 266:24249–24252. 1991.PubMed/NCBI
13	Ingley E: Src family kinases: Regulation of their activities, levels and identification of new pathways. Biochim Biophys Acta. 1784:56–65. 2008.PubMed/NCBI View Article : Google Scholar
14	Rous P: Transmission of a malignant new growth by means of a cell-free filtrate. J Amer Med Assoc. 56:198. 1911.
15	Rous P: A sarcoma of the fowl transmissible by an agent from the tumor cells. J Exp Med. 13:397–411. 1911.PubMed/NCBI View Article : Google Scholar
16	Bittner JJ: The Milk-influence of breast tumors in mice. Science. 95:462–463. 1942.PubMed/NCBI View Article : Google Scholar
17	Gross L: ‘Spontaneous’ leukemia developing in C3H mice following inoculation in infancy, with AK-leukemic extracts, or AK-embrvos. Proc Soc Exp Biol Med. 76:27–32. 1951.PubMed/NCBI
18	Shope RE and Hurst EW: Infectious papillomatosis of rabbits: With a note on the histopathology. J Exp Med. 58:607–624. 1933.PubMed/NCBI View Article : Google Scholar
19	Sweet BH and Hilleman MR: The vacuolating virus, S.V.40. Proc Soc Exp Biol Med. 105:420–427. 1960.PubMed/NCBI View Article : Google Scholar
20	Epstein MA, Achong BG and Barr YM: Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet. 1:702–703. 1964.PubMed/NCBI View Article : Google Scholar
21	Kurth R and Bannert N: Beneficial and detrimental effects of human endogenous retroviruses. Int J Cancer. 126:306–314. 2010.PubMed/NCBI View Article : Google Scholar
22	Boveri T: Zur Frage der Entstehung maligner tumoren. Gustav Fischer, Jena, 1914 (In German).
23	Conney AH, Miller EC and Miller JA: The metabolism of methylated aminoazo dyes. V. Evidence for induction of enzyme synthesis in the rat by 3-methylcholanthrene. Cancer Res. 16:450–459. 1956.PubMed/NCBI
24	Cook JW, Hewett CL and Hieger I: 106. The isolation of a cancer-producing hydrocarbon from coal tar. Parts I, II, and III. J Chemical Soc (Resumed). 395–405. 1933.
25	Miller EC and Miller JA: The presence and significance of bound aminoazo dyes in the livers of rats fed para-dimethylaminoazobenzene. Cancer Res. 7:468–480. 1947.
26	Pott P: Chirurgical observations relative to the cataract, the polypus of the nose, the cancer of the scrotum, the different kinds of ruptures, and the mortification of the toes and feet. Carnegy TJ for Hawes L, Clarke W and Collins R, London, 1775.
27	Yamagiwa K and Ichikawa K: Experimental study of the pathogenesis of carcinoma. CA Cancer J Clin. 27:174–181. 1977.PubMed/NCBI View Article : Google Scholar
28	Temin HM and Rubin H: Characteristics of an assay for rous sarcoma virus and rous sarcoma cells in tissue culture. Virology. 6:669–688. 1958.PubMed/NCBI View Article : Google Scholar
29	Duesberg PH and Vogt PK: Differences between ribonucleic acids of transforming and nontransforming avian tumor viruses. Proc Natl Acad Sci USA. 67:1673–1680. 1970.PubMed/NCBI View Article : Google Scholar
30	Martin GS: Rous sarcoma virus: A function required for maintenance of transformed state. Nature. 227:1021–1023. 1970.PubMed/NCBI View Article : Google Scholar
31	Toyoshima K and Vogt PK: Temperature sensitive mutants of an avian sarcoma virus. Virology. 39:930–931. 1969.PubMed/NCBI View Article : Google Scholar
32	Crawford LV and Crawford EM: Properties of rous sarcoma virus purified by density gradient centrifugation. Virology. 13:227–232. 1961.PubMed/NCBI View Article : Google Scholar
33	Baltimore D: Viral Rna-Dependent DNA Polymerase-Rna-Dependent DNA polymerase in virions of rna tumour viruses. Nature. 226:1209–1211. 1970.
34	Temin HM and Mizutani S: RNA-dependent DNA polymerase in virions of Rous sarcoma virus. Nature. 226:1211–1213. 1970.PubMed/NCBI View Article : Google Scholar
35	Ali M and Baluda MA: Synthesis of avian oncornavirus DNA in infected chicken cells. J Virol. 13:1005–1013. 1974.PubMed/NCBI
36	Baluda MA: Widespread presence, in chickens, of DNA complementary to the RNA genome of avian leukosis viruses. Proc Natl Acad Sci USA. 69:576–580. 1972.PubMed/NCBI View Article : Google Scholar
37	Hayward WS and Hanafusa H: Detection of avian tumor virus RNA in uninfected chicken embryo cells. J Virol. 11:157–167. 1973.PubMed/NCBI
38	Stehelin D, Varmus HE, Bishop JM and Vogt PK: DNA related to the transforming gene(s) of avian sarcoma viruses is present in normal avian DNA. Nature. 260:170–173. 1976.PubMed/NCBI View Article : Google Scholar
39	Baluda MA and Drohan WN: Distribution of deoxyribonucleic acid complementary to the ribonucleic acid of avian myeloblastosis virus in tissues of normal and tumor-bearing chickens. J Virol. 10:1002–1009. 1972.PubMed/NCBI
40	Hanafusa T, Hanafusa H and Miyamoto T: Recovery of a new virus from apparently normal chick cells by infection with avian tumor viruses. Proc Natl Acad Sci USA. 67:1797–1803. 1970.PubMed/NCBI View Article : Google Scholar
41	Perucho M, Goldfarb M, Shimizu K, Lama C, Fogh J and Wigler M: Human-tumor-derived cell lines contain common and different transforming genes. Cell. 27:467–476. 1981.PubMed/NCBI View Article : Google Scholar
42	Shih C, Padhy LC, Murray M and Weinberg RA: Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts. Nature. 290:261–264. 1981.PubMed/NCBI View Article : Google Scholar
43	Shih C, Shilo BZ, Goldfarb MP, Dannenberg A and Weinberg RA: Passage of phenotypes of chemically transformed cells via transfection of DNA and chromatin. Proc Natl Acad Sci USA. 76:5714–5718. 1979.PubMed/NCBI View Article : Google Scholar
44	Reddy EP, Reynolds RK, Santos E and Barbacid M: A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature. 300:149–152. 1982.PubMed/NCBI View Article : Google Scholar
45	Tabin CJ, Bradley SM, Bargmann CI, Weinberg RA, Papageorge AG, Scolnick EM, Dhar R, Lowy DR and Chang EH: Mechanism of activation of a human oncogene. Nature. 300:143–149. 1982.PubMed/NCBI View Article : Google Scholar
46	Raju TN: The Nobel Chronicles. 1989: John Michael Bishop (b 1936) and Harold Eliot Varmus (b 1939). Lancet. 355(1106)2000.PubMed/NCBI View Article : Google Scholar
47	Temin HM: Origin of retroviruses from cellular moveable genetic elements. Cell. 21:599–600. 1980.PubMed/NCBI View Article : Google Scholar
48	Jove R and Hanafusa H: Cell transformation by the viral src oncogene. Annu Rev Cell Biol. 3:31–56. 1987.PubMed/NCBI View Article : Google Scholar
49	Frame MC: Newest findings on the oldest oncogene; how activated src does it. J Cell Sci. 117:989–998. 2004.PubMed/NCBI View Article : Google Scholar
50	Oneyama C and Okada M: MicroRNAs as the fine-tuners of Src oncogenic signalling. J Biochem. 157:431–438. 2015.PubMed/NCBI View Article : Google Scholar
51	Ha M and Kim VN: Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 15:509–524. 2014.PubMed/NCBI View Article : Google Scholar
52	Zhang B, Pan X, Cobb GP and Anderson TA: microRNAs as oncogenes and tumor suppressors. Dev Biol. 302:1–12. 2007.PubMed/NCBI View Article : Google Scholar
53	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006.PubMed/NCBI View Article : Google Scholar
54	Mamane Y, Petroulakis E, LeBacquer O and Sonenberg N: mTOR, translation initiation and cancer. Oncogene. 25:6416–6422. 2006.PubMed/NCBI View Article : Google Scholar
55	Wullschleger S, Loewith R and Hall MN: TOR signaling in growth and metabolism. Cell. 124:471–484. 2006.PubMed/NCBI View Article : Google Scholar
56	Engelman JA: Targeting PI3K signalling in cancer: Opportunities, challenges and limitations. Nat Rev Cancer. 9:550–562. 2009.PubMed/NCBI View Article : Google Scholar
57	Oneyama C, Ikeda J, Okuzaki D, Suzuki K, Kanou T, Shintani Y, Morii E, Okumura M, Aozasa K and Okada M: MicroRNA-mediated downregulation of mTOR/FGFR3 controls tumor growth induced by Src-related oncogenic pathways. Oncogene. 30:3489–3501. 2011.PubMed/NCBI View Article : Google Scholar
58	Doghman M, El Wakil A, Cardinaud B, Thomas E, Wang J, Zhao W, Peralta-Del Valle MH, Figueiredo BC, Zambetti GP and Lalli E: Regulation of insulin-like growth factor - mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. Cancer Res. 70:4666–4675. 2010.PubMed/NCBI View Article : Google Scholar
59	Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, Grazi GL, Pollutri D, Croce CM, Bolondi L and Gramantieri L: miR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 70:5184–5193. 2010.PubMed/NCBI View Article : Google Scholar
60	Hannigan G, Troussard AA and Dedhar S: Integrin-linked kinase: A cancer therapeutic target unique among its ILK. Nat Rev Cancer. 5:51–63. 2005.PubMed/NCBI View Article : Google Scholar
61	Hannigan GE, Leung-Hagesteijn C, Fitz-Gibbon L, Coppolino MG, Radeva G, Filmus J, Bell JC and Dedhar S: Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature. 379:91–96. 1996.PubMed/NCBI View Article : Google Scholar
62	McDonald PC, Fielding AB and Dedhar S: Integrin-linked kinase - essential roles in physiology and cancer biology. J Cell Sci. 121:3121–3132. 2008.PubMed/NCBI View Article : Google Scholar
63	Oneyama C, Morii E, Okuzaki D, Takahashi Y, Ikeda J, Wakabayashi N, Akamatsu H, Tsujimoto M, Nishida T, Aozasa K and Okada M: MicroRNA-mediated upregulation of integrin-linked kinase promotes Src-induced tumor progression. Oncogene. 31:1623–1635. 2012.PubMed/NCBI View Article : Google Scholar
64	Donadelli M, Dando I, Fiorini C and Palmieri M: Regulation of miR-23b expression and its dual role on ROS production and tumour development. Cancer Lett. 349:107–113. 2014.PubMed/NCBI View Article : Google Scholar
65	Azuma K, Tanaka M, Uekita T, Inoue S, Yokota J, Ouchi Y and Sakai R: Tyrosine phosphorylation of paxillin affects the metastatic potential of human osteosarcoma. Oncogene. 24:4754–4764. 2005.PubMed/NCBI View Article : Google Scholar
66	Navon R, Wang H, Steinfeld I, Tsalenko A, Ben-Dor A and Yakhini Z: Novel rank-based statistical methods reveal microRNAs with differential expression in multiple cancer types. PLoS One. 4(e8003)2009.PubMed/NCBI View Article : Google Scholar
67	Shi J, Wang S, Zhao E, Shi L, Xu X and Fang M: Paxillin expression levels are correlated with clinical stage and metastasis in salivary adenoid cystic carcinoma. J Oral Pathol Med. 39:548–551. 2010.PubMed/NCBI View Article : Google Scholar
68	Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, et al: Integrative genomic profiling of human prostate cancer. Cancer Cell. 18:11–22. 2010.PubMed/NCBI View Article : Google Scholar
69	Majid S, Dar AA, Saini S, Arora S, Shahryari V, Zaman MS, Chang I, Yamamura S, Tanaka Y, Deng G, et al: miR-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer. Cancer Res. 72:6435–6446. 2012.PubMed/NCBI View Article : Google Scholar
70	Kokuda R, Watanabe R, Okuzaki D, Akamatsu H and Oneyama C: MicroRNA.137.mediated Src oncogenic signaling promotes cancer progression. Genes Cells: Jul 2, 2018 (Epub ahead of print).
71	Okuzaki D, Yamauchi T, Mitani F, Miyata M, Ninomiya Y, Watanabe R, Akamatsu H and Oneyama C: c-Src promotes tumor progression through downregulation of microRNA-129-1-3p. Cancer Sci. 111:418–428. 2020.PubMed/NCBI View Article : Google Scholar
72	Kennedy S, Clynes M, Doolan P, Mehta JP, Rani S, Crown J and O'Driscoll L: SNIP/p140Cap mRNA expression is an unfavourable prognostic factor in breast cancer and is not expressed in normal breast tissue. Br J Cancer. 98:1641–1645. 2008.PubMed/NCBI View Article : Google Scholar
73	Yu Z, Ye S, Hu G, Lv M, Tu Z, Zhou K and Li Q: The RAF-MEK-ERK pathway: Targeting ERK to overcome obstacles to effective cancer therapy. Future Med Chem. 7:269–289. 2015.PubMed/NCBI View Article : Google Scholar
74	Zhou P, Xiong T, Yao L and Yuan J: MicroRNA-665 promotes the proliferation of ovarian cancer cells by targeting SRCIN1. Exp Ther Med. 19:1112–1120. 2020.PubMed/NCBI View Article : Google Scholar
75	Cao M, Hou D, Liang H, Gong F, Wang Y, Yan X, Jiang X, Wang C, Zhang J, Zen K, et al: miR-150 promotes the proliferation and migration of lung cancer cells by targeting SRC kinase signalling inhibitor 1. Eur J Cancer. 50:1013–1024. 2014.PubMed/NCBI View Article : Google Scholar
76	Zhao X, Xu Y, Sun X, Ma Y, Zhang Y and Wang Y, Guan H, Jia Z, Li Y and Wang Y: miR-17-5p promotes proliferation and epithelial-mesenchymal transition in human osteosarcoma cells by targeting SRC kinase signaling inhibitor 1. J Cell Biochem. 120:5495–5504. 2019.PubMed/NCBI View Article : Google Scholar
77	Yang F, Luo LJ, Zhang L, Wang DD, Yang SJ, Ding L, Li J, Chen D, Ma R, Wu JZ and Tang JH: miR-346 promotes the biological function of breast cancer cells by targeting SRCIN1 and reduces chemosensitivity to docetaxel. Gene. 600:21–28. 2017.PubMed/NCBI View Article : Google Scholar
78	Xu X, Wang W, Su N, Zhu X, Yao J, Gao W, Hu Z and Sun Y: miR-374a promotes cell proliferation, migration and invasion by targeting SRCIN1 in gastric cancer. FEBS Lett. 589:407–413. 2015.PubMed/NCBI View Article : Google Scholar
79	Ma L, Shao Z and Zhao Y: MicroRNA-374a promotes pancreatic cancer cell proliferation and epithelial to mesenchymal transition by targeting SRCIN1. Pathol Res Pract. 215(152382)2019.PubMed/NCBI View Article : Google Scholar
80	Yuan XL, Wen FQ, Chen XW, Jiang XP and Liu SX: miR-373 promotes neuroblastoma cell proliferation, migration, and invasion by targeting SRCIN1. Onco Targets Ther. 12:4927–4936. 2019.PubMed/NCBI View Article : Google Scholar
81	Esquela-Kerscher A and Slack FJ: Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006.PubMed/NCBI View Article : Google Scholar
82	Lin PY, Yu SL and Yang PC: MicroRNA in lung cancer. Br J Cancer. 103:1144–1148. 2010.PubMed/NCBI View Article : Google Scholar
83	Pal MK, Jaiswar SP, Dwivedi VN, Tripathi AK, Dwivedi A and Sankhwar P: MicroRNA: A new and promising potential biomarker for diagnosis and prognosis of ovarian cancer. Cancer Biol Med. 12:328–341. 2015.PubMed/NCBI View Article : Google Scholar
84	Nada S, Okada M, MacAuley A, Cooper JA and Nakagawa H: Cloning of a complementary DNA for a protein-tyrosine kinase that specifically phosphorylates a negative regulatory site of p60c-src. Nature. 351:69–72. 1991.PubMed/NCBI View Article : Google Scholar
85	Nada S, Yagi T, Takeda H, Tokunaga T, Nakagawa H, Ikawa Y, Okada M and Aizawa S: Constitutive activation of Src family kinases in mouse embryos that lack Csk. Cell. 73:1125–1135. 1993.PubMed/NCBI View Article : Google Scholar
86	Mitra SK and Schlaepfer DD: Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol. 18:516–523. 2006.PubMed/NCBI View Article : Google Scholar
87	Fincham VJ, Unlu M, Brunton VG, Pitts JD, Wyke JA and Frame MC: Translocation of Src kinase to the cell periphery is mediated by the actin cytoskeleton under the control of the Rho family of small G proteins. J Cell Biol. 135:1551–1564. 1996.PubMed/NCBI View Article : Google Scholar
88	Harris KF, Shoji I, Cooper EM, Kumar S, Oda H and Howley PM: Ubiquitin-mediated degradation of active Src tyrosine kinase. Proc Natl Acad Sci USA. 96:13738–13743. 1999.PubMed/NCBI View Article : Google Scholar
89	Reinecke J and Caplan S: Endocytosis and the Src family of non-receptor tyrosine kinases. Biomol Concepts. 5:143–155. 2014.PubMed/NCBI View Article : Google Scholar
90	Tu C, Ortega-Cava CF, Winograd P, Stanton MJ, Reddi AL, Dodge I, Arya R, Dimri M, Clubb RJ, Naramura M, et al: Endosomal-sorting complexes required for transport (ESCRT) pathway-dependent endosomal traffic regulates the localization of active Src at focal adhesions. Proc Natl Acad Sci USA. 107:16107–16112. 2010.PubMed/NCBI View Article : Google Scholar
91	Tanaka K, Ito Y, Kajiwara K, Nada S and Okada M: Ubiquitination of Src promotes its secretion via small extracellular vesicles. Biochem Biophys Res Commun: Feb 18, 2020 (Epub ahead of print).
92	Ji H, Greening DW, Barnes TW, Lim JW, Tauro BJ, Rai A, Xu R, Adda C, Mathivanan S, Zhao W, et al: Proteome profiling of exosomes derived from human primary and metastatic colorectal cancer cells reveal differential expression of key metastatic factors and signal transduction components. Proteomics. 13:1672–1686. 2013.PubMed/NCBI View Article : Google Scholar
93	DeRita RM, Zerlanko B, Singh A, Lu H, Iozzo RV, Benovic JL and Languino LR: c-Src, insulin-like growth factor I receptor, G-protein-coupled receptor kinases and focal adhesion kinase are enriched into prostate cancer cell exosomes. J Cell Biochem. 118:66–73. 2017.PubMed/NCBI View Article : Google Scholar
94	Imjeti NS, Menck K, Egea-Jimenez AL, Lecointre C, Lembo F, Bouguenina H, Badache A, Ghossoub R, David G, Roche S, et al: Syntenin mediates SRC function in exosomal cell-to-cell communication. Proc Natl Acad Sci USA. 114:12495–12500. 2017.PubMed/NCBI View Article : Google Scholar
95	Hikita T, Kuwahara A, Watanabe R, Miyata M and Oneyama C: Src in endosomal membranes promotes exosome secretion and tumor progression. Sci Rep. 9(3265)2019.PubMed/NCBI View Article : Google Scholar
96	Roskoski R Jr: Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors. Pharmacol Res. 94:9–25. 2015.PubMed/NCBI View Article : Google Scholar
97	Daud AI, Krishnamurthi SS, Saleh MN, Gitlitz BJ, Borad MJ, Gold PJ, Chiorean EG, Springett GM, Abbas R, Agarwal S, et al: Phase I study of bosutinib, a src/abl tyrosine kinase inhibitor, administered to patients with advanced solid tumors. Clin Cancer Res. 18:1092–1100. 2012.PubMed/NCBI View Article : Google Scholar
98	Moy B, Neven P, Lebrun F, Bellet M, Xu B, Sarosiek T, Chow L, Goss P, Zacharchuk C, Leip E, et al: Bosutinib in combination with the aromatase inhibitor letrozole: A phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer. Oncologist. 19:348–349. 2014.PubMed/NCBI View Article : Google Scholar
99	Taylor JW, Dietrich J, Gerstner ER, Norden AD, Rinne ML, Cahill DP, Stemmer-Rachamimov A, Wen PY, Betensky RA, Giorgio DH, et al: Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma. J Neurooncol. 121:557–563. 2015.PubMed/NCBI View Article : Google Scholar
100	Araujo J and Logothetis C: Dasatinib: A potent SRC inhibitor in clinical development for the treatment of solid tumors. Cancer Treat Rev. 36:492–500. 2010.PubMed/NCBI View Article : Google Scholar
101	Cortes JE, Kim DW, Pinilla-Ibarz J, Le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, et al: A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 369:1783–1796. 2013.PubMed/NCBI View Article : Google Scholar
102	Ahn JS, Lee KH, Sun JM, Park K, Kang ES, Cho EK, Lee DH, Kim SW, Lee GW, Kang JH, et al: A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy. Lung Cancer. 82:455–460. 2013.PubMed/NCBI View Article : Google Scholar
103	Gridelli C, Novello S, Zilembo N, Luciani A, Favaretto AG, De Marinis F, Genestreti G, Crino L, Grossi F, Caffo O, et al: Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients. J Thorac Oncol. 9:733–737. 2014.PubMed/NCBI View Article : Google Scholar
104	Sim MW and Cohen MS: The discovery and development of vandetanib for the treatment of thyroid cancer. Expert Opin Drug Discov. 9:105–114. 2014.PubMed/NCBI View Article : Google Scholar
105	Gucalp A, Sparano JA, Caravelli J, Santamauro J, Patil S, Abbruzzi A, Pellegrino C, Bromberg J, Dang C, Theodoulou M, et al: Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. Clin Breast Cancer. 11:306–311. 2011.PubMed/NCBI View Article : Google Scholar
106	Laurie SA, Goss GD, Shepherd FA, Reaume MN, Nicholas G, Philip L, Wang L, Schwock J, Hirsh V, Oza A, et al: A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: The Princess Margaret Hospital phase II consortium. Clin Lung Cancer. 15:52–57. 2014.PubMed/NCBI View Article : Google Scholar
107	Molina JR, Foster NR, Reungwetwattana T, Nelson GD, Grainger AV, Steen PD, Stella PJ, Marks R, Wright J and Adjei AA: A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621. Lung Cancer. 85:245–250. 2014.PubMed/NCBI View Article : Google Scholar
108	U.S. National Library of Medicine: https://clinicaltrials.gov/. https://clinicaltrials.gov. Accessed July 1, 2020.
109	U.S. National Library of Medicine: Phase I Trial of Afatinib (BIBW 2992) and dasatinib in non-small cell lung cancer (NSCLC). https://clinicaltrials.gov/ Identifier: NCT01999985. https://ClinicalTrials.gov/show/NCT01999985]. Accessed June 14, 2019.
110	U.S. National Library of Medicine: Dasatinib in combination with trastuzumab and paclitaxel in first line treatment of Her2-Positive MBC patients. https://clinicaltrials.gov/ Identifier: NCT01306942. https://ClinicalTrials.gov/show/NCT01306942]. Accessed September 9, 2019.
111	U.S. National Library of Medicine: Trial of dasatinib plus ixabepilone in 2nd or 3rd line metastatic breast cancer. https://clinicaltrials.gov/ Identifier: NCT00924352. https://ClinicalTrials.gov/show/NCT00924352]. Accessed September 29, 2014.
112	U.S. National Library of Medicine: Study of dasatinib and docetaxel in metastatic hormone refractory prostate cancer. https://clinicaltrials.gov/ Identifier: NCT00439270. https://ClinicalTrials.gov/show/NCT00439270]. Accessed November 27, 2013.
113	U.S. National Library of Medicine: Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC). https://clinicaltrials.gov/ Identifier: NCT00826449. https://ClinicalTrials.gov/show/NCT00826449]. Accessed October 21, 2015.
114	U.S. National Library of Medicine: Study evaluating bosutinib-exemestane combination vs exemestane alone in post menopausal women with breast cancer. https://clinicaltrials.gov/ Identifier: NCT00793546. https://ClinicalTrials.gov/show/NCT00793546]. Accessed November 5, 2012.
115	U.S. National Library of Medicine: Study evaluating bosutinib-letrozole combination versus letrozole alone in post menopausal women with breast cancer. https://clinicaltrials.gov/ Identifier: NCT00880009. https://ClinicalTrials.gov/show/NCT00880009]. Accessed November 5, 2012.
116	U.S. National Library of Medicine: Study of bosutinib with capecitabine in solid tumors and locally advanced or metastatic breast cancer. https://clinicaltrials.gov/ Identifier: NCT00959946. https://ClinicalTrials.gov/show/NCT00959946]. Accessed February 22, 2013.
117	U.S. National Library of Medicine: A Multicenter Phase 3, Open-label study of bosutinib versus imatinib in adult patients with newly diagnosed chronic phase chronic myelogenous leukemia. https://clinicaltrials.gov/ Identifier: NCT02130557. https://ClinicalTrials.gov/show/NCT02130557]. Accessed November 14, 2018.
118	U.S. National Library of Medicine: AZD0530 Phase II study in patients with advanced ovarian cancer. https://clinicaltrials.gov/ Identifier: NCT00610714. https://ClinicalTrials.gov/show/NCT00610714]. Accessed September 20, 2011.
119	U.S. National Library of Medicine: Saracatinib and paclitaxel in platinum-resistant ovarian cancer. https://clinicaltrials.gov/ Identifier: NCT01196741. https://ClinicalTrials.gov/show/NCT01196741]. Accessed May 5, 2015.